Transmembrane TNF-α, induction of apoptosis, and the efficacy of TNF-targeting therapies in Crohn's disease

Gastroenterology

Volumn 121, Issue 5, 2001, Pages 1242-1246

  Van Deventer, S J H ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 6; MONOCLONAL ANTIBODY; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL MODEL; APOPTOSIS; CLINICAL TRIAL; COLITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DRUG EFFECT; DRUG TARGETING; EDITORIAL; HUMAN; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL;

EID: 0034761594     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2001.29035     Document Type: Article

References (26)

1. TRAF2-mediated activation of NF-κB by TNF receptor 2 and CD40
2. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-κB activation prevents cell death
3. An essential role for NF-κB in preventing TNF-α-induced cell death
4. NF-κB antiapoptosis: Induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation
5. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab
6. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: A randomised trial
7. Remission of Behcet's syndrome with tumour necrosis factor alpha blocking therapy
8. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease
9. Infliximab for the treatment of fistulas in patients with Crohn's disease
10. Etanercept (p75 soluble tumor necrosis factor receptor: Fc fusion protein) for active Crohn's disease: A randomized double-blind, placebo-controlled trial
11. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway
12. An engineered human antibody to TNF (CDP571) for active Crohn's disease: A randomized double-blind placebo-controlled trial
13. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis
14. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis
15. Death receptors: Signaling and modulation
16. CD95's deadly mission in the immune system
17. The biochemistry of apoptosis
18. Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions
19. A casein kinase 1 motif present in the cytoplasmic domain of members of the tumour necrosis factor ligand family is implicated in "reverse signalling"
20. + T cell clones provides a costimulatory signal for human B cell activation
21. Lamina propria T cells in Crohn's disease and other gastrointestinal inflammation show defective CD2 pathway-induced apoptosis
22. Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalance
23. Decreased Bax expression by mucosal T cells favours resistance to apoptosis in Crohn's disease
24. Infliximab treatment induces apoptosis of activated lamina propria T-lymphocytes in Crohn's disease
25. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivo
26. Anti-interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice